Cagrilintide

5mg Vial

10mg Vial

29 August 2026Updated 29 August 2026

Cagrilintide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Cagrilintide.

Create free account Member login

Full range of benefits for Cagrilintide

Acts as an amylin receptor agonist to enhance satiety

Reduces appetite and caloric intake in clinical studies

Slows gastric emptying, promoting earlier fullness

Associated with body weight reduction in trials

Shows additive weight-loss effects with GLP-1 agonists

May improve glycaemic control when combined with GLP-1 therapy

Favors reduction in fat mass versus lean mass in studies

Once-weekly, long-acting formulation may support adherence

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 12 known interactions

Synergistic(3)Compatible(3)Monitor(3)Avoid(3)

Use with professional oversight

Insulin

Concomitant use can increase hypoglycaemia risk due to reduced appetite and weight loss and delayed gastric emptying, so glucose should be closely monitored and insulin doses titrated.

Sulfonylureas (e.g., glimepiride, gliclazide)

Sulfonylureas increase hypoglycaemia risk when combined with cagrilintide; monitor blood glucose and consider dose reduction as weight and intake change.

Oral medications with narrow therapeutic windows (e.g., warfarin, levothyroxine, oral contraceptives)

Because cagrilintide slows gastric emptying, absorption of certain oral drugs may be altered; monitor INR, TSH, or contraceptive efficacy as clinically indicated.

All interaction categories

Synergistic (3)

Semaglutide (GLP-1 receptor agonist): Semaglutide and cagrilintide have complementary mechanisms (GLP‑1 receptor agonism plus amylin analogue) and clinical trials show additive weight loss and improved glycemic control when combined.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): SGLT2 inhibitors provide an insulin‑independent glycosuric mechanism that can produce additive glucose lowering and modest additional weight loss when used with cagrilintide.
Lifestyle intervention (diet and exercise): Structured dietary restriction and increased physical activity are synergistic with cagrilintide, enhancing weight‑loss efficacy and cardiometabolic benefits.

Compatible (3)

Metformin: Metformin is commonly co‑administered with cagrilintide with no expected pharmacokinetic interactions and is considered a neutral, compatible partner for improving glycaemic control.
DPP‑4 inhibitors (e.g., sitagliptin): DPP‑4 inhibitors have a neutral interaction profile with cagrilintide and can be used concomitantly without specific dose adjustments, though incremental efficacy may be limited.
Statins (e.g., atorvastatin): Statins are pharmacologically compatible with cagrilintide and require no routine modification when combined, apart from standard lipid monitoring.

Monitor (3)

Insulin: Concomitant use can increase hypoglycaemia risk due to reduced appetite and weight loss and delayed gastric emptying, so glucose should be closely monitored and insulin doses titrated.
Sulfonylureas (e.g., glimepiride, gliclazide): Sulfonylureas increase hypoglycaemia risk when combined with cagrilintide; monitor blood glucose and consider dose reduction as weight and intake change.
Oral medications with narrow therapeutic windows (e.g., warfarin, levothyroxine, oral contraceptives): Because cagrilintide slows gastric emptying, absorption of certain oral drugs may be altered; monitor INR, TSH, or contraceptive efficacy as clinically indicated.

Avoid (3)

History of gastroparesis or severe GI motility disorders: Cagrilintide delays gastric emptying and may exacerbate symptoms in patients with gastroparesis or other significant gastrointestinal motility disorders, so use warrants careful evaluation.
GLP‑1 receptor agonists in patients with prior pancreatitis: Although GLP‑1 receptor agonists can be synergistic, in patients with a history of pancreatitis combined use should be approached cautiously because of potential pancreatitis risk signals and overlapping GI effects.
Opioids and anticholinergic agents: Concurrent use of drugs that reduce gastrointestinal motility (opioids, anticholinergics) may potentiate delayed gastric emptying and increase the risk of severe gastrointestinal adverse effects when combined with cagrilintide.